1. Preface
1.1. Report Description
1.1.1. Purpose of the Report
1.1.2. Target Audience
1.1.3. Key Offerings
1.2. Market Segmentation
1.3. Research Methodology
1.3.1. Phase I - Secondary Research
1.3.2. Phase II - Primary Research
1.3.3. Phase III - Expert Panel Review
1.3.4. Assumptions
1.3.5. Approach Adopted

2. Executive Summary
2.1. Market Snapshot: Global Antibody Drug Conjugate Market
2.2. Global Antibody Drug Conjugate Market, By Drug, 2023 (US$ Million)
2.3. Global Antibody Drug Conjugate Market, By Geography, 2023 (US$ Million)
2.4. Attractive Investment Proposition by Geography, 2023

3. Antibody Drug Conjugate Market: Competitive Analysis
3.1. Market Positioning of Key Antibody Drug Conjugate Market Vendors
3.2. Strategies Adopted by Antibody Drug Conjugate Market Vendors
3.3. Key Industry Strategies
4. Antibody Drug Conjugate Market: Macro Analysis & Market Dynamics
4.1. Introduction
4.2. Global Antibody Drug Conjugate Market Value, 2022 - 2032, (US$ Million)
4.3. Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Key Challenges
4.3.4. Key Opportunities
4.4. Impact Analysis of Drivers and Restraints
4.5. See-Saw Analysis
4.6. Porter's Five Force Model
4.6.1. Supplier Power
4.6.2. Buyer Power
4.6.3. Threat Of Substitutes
4.6.4. Threat Of New Entrants
4.6.5. Competitive Rivalry
4.7. PESTEL Analysis
4.7.1. Political Landscape
4.7.2. Economic Landscape
4.7.3. Technology Landscape
4.7.4. Legal Landscape
4.7.5. Social Landscape

5. Antibody Drug Conjugate Market: By Drug, 2022-2032, USD (Million)
5.1. Market Overview
5.2. Growth & Revenue Analysis: 2023 Versus 2032
5.3. Market Segmentation
5.3.1. Kadcyla
5.3.2. Adcetris
5.3.3. Pipeline Analysis of Antibody Drug Conjugate


6. North America Antibody Drug Conjugate Market, 2022-2032, USD (Million)
6.1. Market Overview
6.2. Antibody Drug Conjugate Market: By Drug, 2022-2032, USD (Million)
6.3.Antibody Drug Conjugate Market: By Region, 2022-2032, USD (Million)
6.3.1.North America
6.3.1.1. U.S.
6.3.1.1.1. Antibody Drug Conjugate Market: By Drug, 2022-2032, USD (Million)
6.3.1.2. Canada
6.3.1.2.1. Antibody Drug Conjugate Market: By Drug, 2022-2032, USD (Million)
6.3.1.3. Rest of North America
6.3.1.3.1. Antibody Drug Conjugate Market: By Drug, 2022-2032, USD (Million)

7. UK and European Union Antibody Drug Conjugate Market, 2022-2032, USD (Million)
7.1. Market Overview
7.2. Antibody Drug Conjugate Market: By Drug, 2022-2032, USD (Million)
7.3.Antibody Drug Conjugate Market: By Region, 2022-2032, USD (Million)
7.3.1.UK and European Union
7.3.1.1. UK
7.3.1.1.1. Antibody Drug Conjugate Market: By Drug, 2022-2032, USD (Million)
7.3.1.2. Germany
7.3.1.2.1. Antibody Drug Conjugate Market: By Drug, 2022-2032, USD (Million)
7.3.1.3. Spain
7.3.1.3.1. Antibody Drug Conjugate Market: By Drug, 2022-2032, USD (Million)
7.3.1.4. Italy
7.3.1.4.1. Antibody Drug Conjugate Market: By Drug, 2022-2032, USD (Million)
7.3.1.5. France
7.3.1.5.1. Antibody Drug Conjugate Market: By Drug, 2022-2032, USD (Million)
7.3.1.6. Rest of Europe
7.3.1.6.1. Antibody Drug Conjugate Market: By Drug, 2022-2032, USD (Million)

8. Asia Pacific Antibody Drug Conjugate Market, 2022-2032, USD (Million)
8.1. Market Overview
8.2. Antibody Drug Conjugate Market: By Drug, 2022-2032, USD (Million)
8.3.Antibody Drug Conjugate Market: By Region, 2022-2032, USD (Million)
8.3.1.Asia Pacific
8.3.1.1. China
8.3.1.1.1. Antibody Drug Conjugate Market: By Drug, 2022-2032, USD (Million)
8.3.1.2. Japan
8.3.1.2.1. Antibody Drug Conjugate Market: By Drug, 2022-2032, USD (Million)
8.3.1.3. India
8.3.1.3.1. Antibody Drug Conjugate Market: By Drug, 2022-2032, USD (Million)
8.3.1.4. Australia
8.3.1.4.1. Antibody Drug Conjugate Market: By Drug, 2022-2032, USD (Million)
8.3.1.5. South Korea
8.3.1.5.1. Antibody Drug Conjugate Market: By Drug, 2022-2032, USD (Million)
8.3.1.6. Rest of Asia Pacific
8.3.1.6.1. Antibody Drug Conjugate Market: By Drug, 2022-2032, USD (Million)

9. Latin America Antibody Drug Conjugate Market, 2022-2032, USD (Million)
9.1. Market Overview
9.2. Antibody Drug Conjugate Market: By Drug, 2022-2032, USD (Million)
9.3.Antibody Drug Conjugate Market: By Region, 2022-2032, USD (Million)
9.3.1.Latin America
9.3.1.1. Brazil
9.3.1.1.1. Antibody Drug Conjugate Market: By Drug, 2022-2032, USD (Million)
9.3.1.2. Mexico
9.3.1.2.1. Antibody Drug Conjugate Market: By Drug, 2022-2032, USD (Million)
9.3.1.3. Rest of Latin America
9.3.1.3.1. Antibody Drug Conjugate Market: By Drug, 2022-2032, USD (Million)

10. Middle East and Africa Antibody Drug Conjugate Market, 2022-2032, USD (Million)
10.1. Market Overview
10.2. Antibody Drug Conjugate Market: By Drug, 2022-2032, USD (Million)
10.3.Antibody Drug Conjugate Market: By Region, 2022-2032, USD (Million)
10.3.1.Middle East and Africa
10.3.1.1. GCC
10.3.1.1.1. Antibody Drug Conjugate Market: By Drug, 2022-2032, USD (Million)
10.3.1.2. Africa
10.3.1.2.1. Antibody Drug Conjugate Market: By Drug, 2022-2032, USD (Million)
10.3.1.3. Rest of Middle East and Africa
10.3.1.3.1. Antibody Drug Conjugate Market: By Drug, 2022-2032, USD (Million)

11. Company Profile
11.1. Seattle Genetics, Inc.
11.1.1. Company Overview
11.1.2. Financial Performance
11.1.3. Product Portfolio
11.1.4. Strategic Initiatives
11.2. F. Hoffman-La Roche
11.2.1. Company Overview
11.2.2. Financial Performance
11.2.3. Product Portfolio
11.2.4. Strategic Initiatives
11.3. ImmunoGen, Inc.
11.3.1. Company Overview
11.3.2. Financial Performance
11.3.3. Product Portfolio
11.3.4. Strategic Initiatives
11.4. Bayer AG
11.4.1. Company Overview
11.4.2. Financial Performance
11.4.3. Product Portfolio
11.4.4. Strategic Initiatives
11.5. Novartis AG
11.5.1. Company Overview
11.5.2. Financial Performance
11.5.3. Product Portfolio
11.5.4. Strategic Initiatives
11.6. Takeda Pharmaceutical Company Limited
11.6.1. Company Overview
11.6.2. Financial Performance
11.6.3. Product Portfolio
11.6.4. Strategic Initiatives
11.7. Immunomedics, Inc.
11.7.1. Company Overview
11.7.2. Financial Performance
11.7.3. Product Portfolio
11.7.4. Strategic Initiatives
11.8. Agensys, Inc.
11.8.1. Company Overview
11.8.2. Financial Performance
11.8.3. Product Portfolio
11.8.4. Strategic Initiatives
11.9. Concortis Biotherapeutics
11.9.1. Company Overview
11.9.2. Financial Performance
11.9.3. Product Portfolio
11.9.4. Strategic Initiatives
11.10. NBE-Therapeutics
11.10.1. Company Overview
11.10.2. Financial Performance
11.10.3. Product Portfolio
11.10.4. Strategic Initiatives
11.11. Pfizer
11.11.1. Company Overview
11.11.2. Financial Performance
11.11.3. Product Portfolio
11.11.4. Strategic Initiatives
11.12. Polytherics (An Abzena Company)
11.12.1. Company Overview
11.12.2. Financial Performance
11.12.3. Product Portfolio
11.12.4. Strategic Initiatives
11.13. Oxford BioTherapeutics
11.13.1. Company Overview
11.13.2. Financial Performance
11.13.3. Product Portfolio
11.13.4. Strategic Initiatives
11.14. Spirogen (MedImmune)
11.14.1. Company Overview
11.14.2. Financial Performance
11.14.3. Product Portfolio
11.14.4. Strategic Initiatives
11.15. Others
11.15.1. Company Overview
11.15.2. Financial Performance
11.15.3. Product Portfolio
11.15.4. Strategic Initiatives